Improved Outcomes With Olaparib Plus Bevacizumab Maintenance in Ovarian Cancer
Adding the PARP inhibitor olaparib to bevacizumab maintenance therapy for ovarian cancer among patients who have responded to platinum-taxane chemotherapy improves outcomes regardless of when surgery took place, according to an...